News
Public · Published
Seres Therapeutics, Inc. expected to post a loss of 100 cents a share - Earnings Preview
Seres Therapeutics is expected to report results on November 3 for the quarter ending September 30, 2026. Analysts expect revenue of $6.35 million, up 1,709.1% from $351 thousand a year ago, and a loss of 100 cents a share.
Published:
Updated:
What happened
Seres Therapeutics is expected to report results on November 3 for the quarter ending September 30, 2026. Analysts expect revenue of $6.35 million, up 1,709.1% from $351 thousand a year ago, and a loss of 100 cents a share.
Confirmed
Global impact / market context
A loss of 100 cents a share means the company is expected to spend more than it earns per share, so investors will watch whether revenue growth narrows that loss. The strong 'buy' rating and $17.00 median price target suggest analysts see room for recovery.
Analyst inference
The $17.00 median price target is about 771.8% above the last closing price of $1.95, a very wide gap that signals high uncertainty. Revenue is expected to jump from a tiny base, so a small dollar change can produce a large percentage swing.
Analyst inference
What to watch
- Analysts expect a loss of 100 cents a share and revenue of $6.35 million for the quarter ending September 30, 2026, based on estimates from two analysts using LSEG data. Confirmed
- Watch whether the company confirms the November 3 report date and whether actual revenue lands near the $6.35 million estimate, since missing it could weaken the case for the current 'buy' rating. Proposed
- Because the $17.00 target is far above the $1.95 close, any sign that the loss is wider than expected could pressure the stock, while meeting estimates may support it. Analyst inference
Evidence
- Original source link unavailable